Tumor markers: reclassification and new approaches to evaluation (Q33543590)

27 July 2017

1 reference

title

Tumor markers: reclassification and new approaches to evaluation (English)

1 reference

27 July 2017

Aziz KJ

1

1 reference

27 July 2017

1 January 1998

1 reference

Advances in Clinical Chemistry

27 July 2017

1 reference

27 July 2017

33

1 reference

27 July 2017

169-199

1 reference

Tumour markers: current status and future applications.

27 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2808%2960208-5

7 January 2021

Clinical Applications of Serum Tumor Markers

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2808%2960208-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2808%2960208-5

7 January 2021

Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2808%2960208-5

7 January 2021

The logistic modeling of sensitivity, specificity, and predictive value of a diagnostic test

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2808%2960208-5

7 January 2021

Evaluation of a palpable breast mass

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2808%2960208-5

7 January 2021

The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2808%2960208-5

7 January 2021

Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2808%2960208-5

7 January 2021

Serum (circulating) tumor markers for breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2808%2960208-5

7 January 2021

Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2808%2960208-5

7 January 2021

Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2808%2960208-5

7 January 2021

Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2808%2960208-5

7 January 2021

Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2808%2960208-5

7 January 2021

Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2808%2960208-5

7 January 2021

Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2808%2960208-5

7 January 2021

The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2808%2960208-5

7 January 2021

Seminal Plasma Protein p30: Simplified Purification and Evidence for Identity with Prostate Specific Antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2808%2960208-5

7 January 2021

Colorectal cancer screening: clinical guidelines and rationale

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2808%2960208-5

7 January 2021

10.1016/S0065-2423(08)60208-5

Identifiers

DOI

0 references

PubMed ID

10086177

1 reference

PubMed ID

10086177